OTCMKTS:MKGAF Merck KGaA Q4 2023 Earnings Results & Report $167.21 +9.24 (+5.85%) As of 10/20/2026 03:55 PM Eastern Merck KGaA missed analyst earnings expectations but beat on revenue in its Q4 2023 results, released March 7, 2024. The company reported EPS of $1.99 versus the $2.15 consensus estimate, while revenue of $5.63 billion topped the $5.58 billion estimate by $41.42 million. Research:Profile Earnings Announcement Details QuarterQ4 2023Report DateMarch 7, 2024 Merck KGaA EPS ResultsActual EPS$1.99Consensus EPS $2.15Beat/MissMissed by -$0.16One Year Ago EPSN/AMerck KGaA Revenue ResultsActual Revenue$5.63 billionExpected Revenue$5.58 billionBeat/MissBeat by +$41.42 millionYoY Revenue GrowthN/AUpcoming EarningsMerck KGaA's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Merck KGaA Q4 2023 Earnings FAQ Did Merck KGaA beat earnings estimates for Q4 2023? Merck KGaA (OTCMKTS:MKGAF) reported earnings of $1.99 per share for Q4 2023, missing the consensus estimate of $2.15. The report was announced on Thursday, March 7, 2024. What was Merck KGaA's revenue for Q4 2023? Merck KGaA reported revenue of $5.63 billion for Q4 2023, against a consensus estimate of $5.58 billion. When is Merck KGaA's next earnings date? Merck KGaA's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Merck KGaA on the company's earnings history page. Merck KGaA Earnings HeadlinesSilence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNAOctober 19 at 5:29 PM | seekingalpha.comGermany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 BillionOctober 19 at 8:48 AM | wsj.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Time to Sell?October 12, 2026 | americanbankingnews.comMedicare drug pricing model to affect only four firms after Trump’s MFN policyOctober 2, 2026 | msn.comEvinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical DevelopmentJuly 29, 2026 | businesswire.comSee More Merck KGaA Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email. Email Address About Merck KGaAMerck KGaA (OTCMKTS:MKGAF) is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company. Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products. The Life Science business supplies laboratory products, equipment, services and technologies used in pharmaceutical manufacturing, biotechnology, research and academic laboratories. The Electronics business develops materials and solutions for the semiconductor and display industries, including specialty chemicals, semiconductor materials and liquid-crystal technologies. Merck KGaA serves customers in markets around the world through research, manufacturing and commercial operations across multiple regions. Belén Garijo has served as the company’s chief executive officer and chair of its executive board since 2021.View Merck KGaA ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Halliburton Gains Traction: Multiyear Upcycle AheadMeta Platforms' AI Comeback Faces an Earnings Test—And a $10 Billion ChargeCarMax's Double Upgrade Could Signal a Bigger TurnaroundD-Wave Stock Has 2 New Reasons for Investors to Pay AttentionTesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging Upcoming Earnings Comcast (10/22/2026)Spotify Technology (10/22/2026)Procter & Gamble (10/22/2026)Valero Energy (10/22/2026)Barclays (10/22/2026)Blackstone (10/22/2026)Nasdaq (10/22/2026)Bloom Energy (10/22/2026)Comfort Systems USA (10/22/2026)Honeywell International (10/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
